Shield Therapeutics said that its oral ferric iron therapy Feraccru proved to be non-inferior to Ferinject (ferric carboxymaltose or FCM), a widely used intravenously delivered iron replacement therapy, in the AEGIS-H2H non-inferiority study.
Horizon Pharma plc (Nasdaq: HZNP) today announced topline results from its Phase 3 confirmatory trial evaluating teprotumumab for the treatment of active thyroid eye disease (TED).
A clinical trial held in the UK in patients with Parkinson’s Disease showed that it could be possible to restore damaged neurons by boosting the levels of a naturally-occurring protein called Glial Cell Line Derived Neurotrophic Factor (GDNF).
Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to commence human pharmacokinetics studies for the Company's lead asset NXP001.
The Phase III THEMIS trial met its primary endpoint and demonstrated that Brilinta (ticagrelor), taken in conjunction with aspirin, showed a statistically-significant reduction in a composite of major adverse cardiovascular events (MACE) compared to aspirin alone.
Sosei Group announced that the first healthy subject has been dosed with a small molecule HTL0030310 in a Phase I clinical study, marking the start of a new in-house clinical program targeting endocrine disorders, including Cushing’s disease.
Innovent has entered into a collaboration with Shenzhen Chipscreen Biosciences to evaluate a combination therapy made up of their respective drugs in colorectal cancer patients.
Bionomics has announced that further data analysis of its phase 2 post traumatic stress disorder (PTSD) trial demonstrated the potential for significant patient benefit when drug exposure is adequate.
Pfizer and Merck have announced that Bavencio (avelumab) plus Inlyta (axitinib) has improved median progression-free survival (PFS) in renal carcinoma study.
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced CAROLINA (CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with type 2 diabetes) met its primary endpoint, defined as non-inferiority for Tradjenta (linagliptin) versus glimepiride in time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (3P-MACE).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.